This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) An epothilone compound of formula I,

in which

R⁴ means hydrogen, C₁-C₁₀ alkyl, aryl, C₇-C₂₀ aralkyl,

 R^5 means hydrogen, C_1 - C_{10} alkyl, aryl, C_7 - C_{20} aralkyl,

wherein, for R^4 and R^5 , aryl is phenyl, wherein said phenyl is optionally substituted in one or more places by halogen, OH, O-alkyl, CO₂H, CO₂-alkyl, -NH₂, -NO₂, -N₃, -CN, C₁-C₂₀ alkyl, C₁-C₂₀ acyl and/or C₁-C₂₀ acyloxy groups, and

wherein, for R⁴ and R⁵, aralkyl is benzyl[[5]] or phenylethyl, wherein said benzyl[[5]] or phenylethyl is optionally substituted in one or more places by halogen, OH, O-alkyl, CO₂H, CO₂-alkyl, -NO₂, -N₃, -CN, C₁-C₂₀ alkyl, C₁-C₂₀ acyl and/or C₁-C₂₀ acyloxy groups,

R⁶, R⁷ each mean a hydrogen atom, or together mean an additional bond to result in a double bond on the ring between their two positions or together mean an oxygen atom to provide an epoxide ring,

R⁸ means a methyl group or hydrogen,

and at the same time, R^{1a} and R^{1b} together stand for a trimethylene group, R² stands for a phenyl or benzyl radical, and X stands for a 2 pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl radical or

at the same time R^{1a} and R^{1b} together stand for a trimethylene group, R^2 stands for a methyl, ethyl or propyl group and X stands for a 2-pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl radical or

at the same time R^{1a} and R^{1b} in each case stand for a methyl group, R^2 stands for a methyl, ethyl or propyl radical, and X stands for a $\frac{2-pyridyl}{2}$, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl radical,

whereby wherein the nitrogen atom and/or the sulfur atom in X can be present in oxidized form, and whereby

wherein, if R² and R⁸ each are simultaneously not-in each case mean a methyl radical,

X can be only one 2-pyridyl radical that is optionally oxidized on the nitrogen atom,
or a stereoisomer thereof.

- 2. (Previously presented) A compound according to claim 1, in which R⁸ is a hydrogen atom.
- 3. (Previously presented) A compound according to claim 1, in which R⁸ is a methyl group.
- 4. (Previously presented) A compound according to claim 1, in which R² is an ethyl group.
- 5. (Previously presented) A compound according to claim 1, in which R² is a propyl group.

6-16. (Cancelled)

- 17. (Currently amended) A compound according to claim $\underline{2}$ 10, in which R^2 is a propyl group.
- 18. (Previously presented) A compound according to claim 1, in which R⁵ is a methyl group.
 - 19. (Cancelled)
- 20. (Currently amended) A compound of formula I[[5]] of claim 1, which is:

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-16-(2-(2-methyl-4-

thiazolyl)ethenyl)-1-oxa-5,5,7,9,13-pentamethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-3-(2-(2-methyl-4-

thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(2-(2-methyl-4-

thiazolyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16-(2-(2-methyl-4-

thiazolyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-ethyl-3-(2-(2-methyl-4-

thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(2-(2-methyl-4-

thiazolyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

```
(4S,7R,8S,9S,13(E or Z),16S(E)) 4,8-Dihydroxy 16 (1-methyl-2 (2 pyridyl)ethenyl)

1-oxa 5,5 (1,3-trimethylene) 7,9,13-trimethyl cyclohexadec-13-ene 2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy 3 (1-methyl-2-(2-
```

pyridyl)ethenyl) 8,8-(1,3-trimethylene) 10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca 5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl) 8,8-(1,3 trimethylene) 10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-16-(2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-7,9,13-trimethyl-cyclohexadec-13-ene-2,6-dione,

 $(1(S \ or \ R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,$

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-10,12,16-trimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E)) 4,8 Dihydroxy 16 (2 (2-pyridyl)ethenyl) 1 oxa-5,5,7,9,13-pentamethyl-cyclohexadec 13-ene 2,6 dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11 Dihydroxy-3 (2 (2 pyridyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11 Dihydroxy 3 (2 (2-pyridyl)ethenyl)-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9 dione,

(4S,7R,8S,9S,13(E or Z),16S(E)) 4,8-Dihydroxy-7 ethyl-16 (1 methyl 2 (2-pyridyl)ethenyl) 1 oxa 5,5 (1,3-trimethylene) 9,13-dimethyl-cyclohexadec 13 ene 2,6-dione.

(1(S or R),3S(E),7S,10R,11S,12S,16R) 7,11 Dihydroxy 10 ethyl-3 (1 methyl-2 (2-pyridyl)ethenyl) 8,8 (1,3 trimethylene) 12,16 dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9 dione,

(1(R-or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8 (1,3 trimethylene) 12,16 dimethyl-4,17 dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16-(2-(2-methyl-4-thiazolyl)ethenyl)-1-oxa-5,5-(1,3-trimethylene)-9,13-dimethyl-cyclohexadec-13-ene-2,6-dione,

dioxabicyclo[14.1.0]heptadeca-5,9-dione, or

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3-(2-(2-methyl-4-thiazolyl)ethenyl)-8,8-(1,3-trimethylene)-12,16-dimethyl-4,17-

dioxabicyclo[14.1.0]heptadeca-5,9-dione-

(4S,7R,8S,9S,13(E or Z),16S(E))-4,8-Dihydroxy-7-ethyl-16 (2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-ethyl-3-(2-(2-pyridyl)ethenyl) 8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S) 7,11 Dihydroxy 10 ethyl-3 (2-(2-

 $\underline{pyridyl)} ethenyl)-8, 8, 12, 16-tetramethyl-4, 17-dioxabicyclo [14.1.0] heptadeca-5, 9-dione,$

(4S,7R,8S,9S,13(E or Z),16S(E)) 4,8 Dihydroxy-7 ethyl 16 (2-(2 pyridyl)ethenyl) 1-oxa-5,5-(1,3 trimethylene) 9,13 dimethyl-cyclohexadec 13 ene-2,6-dione,

(1(S or R),3S(E),7S,10R,11S,12S,16R) 7,11 Dihydroxy 10 ethyl-3 (2 (2-pyridyl)ethenyl)-8,8 (1,3 trimethylene) 12,16 dimethyl 4,17 dioxabicyclo[14.1.0]heptadeca-5,9 dione,

(1(R or S),3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-ethyl-3 (2 (2-pyridyl)ethenyl) 8,8 (1,3-trimethylene) 12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(4S,7R,8S,9S,13Z,16S(E)) 4,8 Dihydroxy 16 (1 methyl 2 (2 pyridyl)ethenyl) 1 oxa-7-propyl 5,5,9,13-tetramethyl cyclohexadec-13 ene 2,6 dione,

(1S,3S(E),7S,10R,11S,12S,16R)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-N-oxidopyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione, (1R,3S(E),7S,10R,11S,12S,16S)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-N-oxidopyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione, (1S,3S(E),7S,10R,11S,12S,16R)-10-Propyl-7,11-dihydroxy-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9-dione,

(1R,3S(E),7S,10R,11S,12S,16S) 10 Propyl-7,11 dihydroxy-3-(1 methyl 2-(2-pyridyl)ethenyl) 8,8,12,16 tetramethyl-4,17 dioxabicyclo[14.1.0]heptadecane-5,9 dione,

(4S,7R,8S,9S,13E,16S(E)) 4,8 Dihydroxy-16 (1-methyl 2 (2 pyridyl)ethenyl) 1-oxa-

7-propyl-5,5,9,13-tetramethyl-cyclohexadec-13-ene-2,6-dione.

(1R,3S(E),7S,10R,11S,12S,16R) 10 Propyl-7,11-dihydroxy-3 (1-methyl 2 (2 N-oxidopyridyl)ethenyl) 8,8,12,16 tetramethyl 4,17-dioxabicyclo[14.1.0]heptadeca 5,9 dione, (1S,3S(E),7S,10R,11S,12S,16S) 10 Propyl-7,11 dihydroxy-3 (1-methyl-2-(2-N-oxidopyridyl)ethenyl) 8,8,12,16 tetramethyl-4,17-dioxabicyclo[14.1.0]heptadeca-5,9 dione, (1R,3S(E),7S,10R,11S,12S,16R)-10 Propyl-7,11-dihydroxy-3 (1-methyl-2-(2-pyridyl)ethenyl) 8,8,12,16 tetramethyl-4,17-dioxabicyclo]14.1.0]heptadeca-5,9 dione, or

(1S,3S(E),7S,10R,11S,12S,16S)-10 Propyl-7,11 dihydroxy-3 (1 methyl-2 (2 pyridyl)ethenyl) 8,8,12,16 tetramethyl-4,17 dioxabicyclo[14.1.0]heptadeca-5,9 dione.

21. (Currently amended) A pharmaceutical composition comprising at least one compound of formula I according to claim 1 and above as well as a pharmaceutically compatible vehicle.

22. (Canceled)

- 23. (Previously presented) A method for preparing a pharmaceutical composition comprising bringing together a pharmaceutically acceptable carrier and agent which comprises formulating a compound of formula I according to claim 1 in a form suitable for pharmaceutical administration.
- 24. (New) A pharmaceutical composition comprising a compound of claim 20 and a pharmaceutically compatible vehicle.
 - 25. (New) A compound according to claim 1, in which X is 2-methyl-4-thiazolyl.
- **26.** (New) A compound according to claim 1, in which X is 2-methyl-4-oxazolyl radical.

- 27. (New) A compound according to claim 1, in which R^{1a} and R^{1b} in each case stand for a methyl group.
- 28. (New) A compound according to claim 1, in which R^{1a} and R^{1b} together stand for a trimethylene group.
- 29. (New) A compound according to claim 1, in which R⁶ and R⁷ together mean an oxygen atom to provide an epoxide ring.
- 30. (New) A compound according to claim 25, in which R⁶ and R⁷ together mean an oxygen atom to provide an epoxide ring.
- 31. (New) A compound according to claim 26, in which R⁶ and R⁷ together mean an oxygen atom to provide an epoxide ring.
- 32. (New) A compound according to claim 27, in which R⁶ and R⁷ together mean an oxygen atom to provide an epoxide ring.
- 33. (New) A compound according to claim 28, in which R⁶ and R⁷ together mean an oxygen atom to provide an epoxide ring.